Drug Profile

RG 6341

Alternative Names: GDC-6599; RG-6341; RO 7441345

Latest Information Update: 08 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Roche
Class 1 ring heterocyclic compounds; Antiasthmatics; Antitussives; Chlorobenzenes; Oxadiazoles; Purines; Small molecules
Mechanism of Action TRPA1 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

08 Nov 2024 Discontinued - Phase-II for Cough in USA, Australia, United Kingdom, Canada (PO)
21 Oct 2024 Genentech completes a phase-IIa trial in Cough in Australia, Canada, UK and USA (PO) (NCT05660850),
09 May 2024 Roche plans to file regulatory application for Chronic cough, in or after 2027 (Roche pipeline, May 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com